Tempus entered a multi‑year collaboration with Whitehawk Therapeutics to apply Tempus’ de‑identified multimodal real‑world database to guide biomarker discovery and indication prioritization across Whitehawk’s ADC portfolio. The partnership will focus on RNA and immunohistochemistry (IHC) concordance for validated ADC targets and support clinical trial design by identifying patient populations with high unmet need. Whitehawk said the collaboration will help establish RNA testing as an objective, reproducible, and scalable alternative to IHC for patient selection. The work aims to refine target expression understanding in lung and gynecological cancers and optimize enrollment for upcoming ADC trials. Real‑world multimodal datasets used for target‑expression analyses can shorten go/no‑go decisions and reduce trial screening failures by improving upfront patient selection.